Market cap
₹256 Cr
Revenue (TTM)
₹2,202 Cr
P/E Ratio
3.3
P/B Ratio
0.6
Div. Yield
0 %
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
256 | 75 | 50 | 49 | 33,955 |
Revenue (₹ Cr) |
2,202 | 1 | 35 | 18 | 4,974 |
Net Profit (₹ Cr) |
48.11 | 1.49 | 5.90 | -1.19 | 804.14 |
Net Margin (%) |
2.18 | 67.60 | 15.67 | -5.82 | 15.54 |
RoE (%) |
18.30 | 3.36 | 14.76 | -- | 18.21 |
Price to Earnings |
3.29 | 50.27 | 8.40 | -- | 42.49 |
Price-To-Book |
0.62 | 1.65 | 1.19 | -10.54 | 6.88 |
Income Statement (₹ Cr)
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Operating Revenue
|
2,201.62 | 6.16 | 33.99 | 28.20 | 4,612.63 |
|
Total Income
|
2,204.80 | 6.18 | 36.34 | 28.24 | 4,671.80 |
|
Total Expenditure
|
2,115.50 | 5.56 | 29.88 | 27.95 | 3,765.88 |
|
EBITDA
|
86.11 | 0.60 | 4.11 | 0.25 | 846.75 |
|
Depreciation
|
0.23 | 0.03 | 0.36 | 1.03 | 54.97 |
|
EBIT
|
85.88 | 0.56 | 3.75 | -0.78 | 791.78 |
|
Interest
|
23.45 | 0.00 | 0.34 | 0.59 | 44.77 |
|
Other Income
|
3.19 | 0.02 | 2.35 | 0.04 | 59.17 |
|
Exceptional Items
|
-- | -- | -- | -1.07 | -- |
|
Profit before Tax
|
65.62 | 0.58 | 5.77 | -2.40 | 806.18 |
|
Provision for Tax
|
17.51 | 0.15 | 1.52 | -0.30 | 251.08 |
|
Profit after Tax
|
48.11 | 0.43 | 4.25 | -2.09 | 555.10 |
Liabilities (₹ Cr)
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
332.84 | 44.83 | 35.56 | -1.99 | 3,721.74 |
|
Minority Interest
|
-- | -- | -- | -- | 49.20 |
|
Non-Current Liabilities
|
94.84 | 1.38 | 0.57 | 7.51 | 593.04 |
|
Current Liabilities
|
825.84 | 0.69 | 6.95 | 13.04 | 736.24 |
|
Total Liabilities
|
1,253.58 | 46.92 | 43.07 | 18.75 | 5,100.22 |
Assets (₹ Cr)
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2.76 | 0.05 | 2.67 | 8.56 | 2,817.58 |
|
Current Assets
|
1,250.77 | 46.85 | 40.40 | 10.00 | 2,282.64 |
|
Total Assets
|
1,253.58 | 46.92 | 43.07 | 18.75 | 5,100.22 |
|
Total Debt*
|
409.25 | 0.90 | 4.21 | 8.09 | 308.70 |
|
Net Current Assets
|
424.93 | 46.16 | 33.46 | -3.03 | 1,546.40 |
|
Contingent Liabilities
|
333.59 | 0.41 | 1.09 | -- | 50.60 |
Cashflow (₹ Cr)
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-116.02 | 2.11 | -5.83 | -0.96 | 446.86 |
|
Cash Flow from Investing Activities
|
-0.28 | -20.97 | 0.46 | -0.70 | -235.20 |
|
Cash from Financing Activities
|
181.01 | 43.67 | 1.35 | 1.40 | -271.49 |
|
Net Cash Inflow / Outflow
|
64.70 | 24.81 | -4.02 | -0.26 | -59.84 |
Ratios
Profitability Ratios
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
ROCE (%)
|
14.46 | 2.44 | 16.58 | -29.88 | 22.17 |
|
ROE (%)
|
18.30 | 1.87 | 12.58 | 0.00 | 16.62 |
|
ROA (%)
|
4.69 | 1.70 | 10.57 | -12.36 | 11.16 |
|
EBIT Margin (%)
|
4.06 | 10.02 | 19.01 | 1.04 | 19.64 |
|
Net Margin (%)
|
2.18 | 6.98 | 11.68 | -7.41 | 11.88 |
|
Cash Profit Margin (%)
|
2.20 | 7.56 | 13.54 | -3.77 | 13.23 |
Growth Ratios
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
43.44 | -64.31 | -8.18 | 155.17 | 10.22 |
|
EBIT Growth (%)
|
49.25 | 62.49 | -22.82 | 108.86 | 31.75 |
|
Net Profit Growth (%)
|
60.12 | 68.04 | -27.53 | 63.59 | 35.17 |
|
EPS Growth (%)
|
17.93 | -42.03 | -27.53 | 63.59 | 34.94 |
|
Book Value Growth (%)
|
72.58 | 3,563.74 | 11.34 | -346.40 | 19.46 |
Valuation Ratios
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Price / Earnings
|
11.83 | 141.99 | 17.28 | 0.00 | 37.68 |
|
Price / Book Value
|
1.71 | 1.37 | 2.06 | -5.86 | 5.76 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.87 | 0.00 | 0.14 |
|
EV/EBITDA
|
8.21 | 59.87 | 11.15 | 80.88 | 22.71 |
|
Market Cap (₹ Cr)
|
568.90 | 61.28 | 73.37 | 15.80 | 20,933.97 |
Solvency Ratios
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.23 | 0.02 | 0.12 | -4.07 | 0.08 |
|
Short term debt to equity ratio
|
0.93 | -- | 0.10 | -- | 0.08 |
|
Current Ratio
|
1.51 | 67.45 | 5.82 | 0.77 | 3.10 |
|
Quick Ratio
|
0.92 | 67.45 | 5.55 | 0.51 | 2.31 |
|
Interest Coverage
|
3.80 | 371.96 | 18.07 | -3.09 | 19.01 |
Operating Efficiency Ratios
| Shiv Texchem | IEL | Vasundhara Rasayan | Parmax Pharma | Himadri Speciality | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.19 | 0.13 | 12.22 | 4.53 | 13.72 |
|
Asset Turnover
|
2.15 | 0.24 | 0.85 | 1.66 | 0.93 |
|
Receivable days
|
51.95 | 49.30 | 55.72 | 20.01 | 50.98 |
|
Inventory Days
|
73.91 | 0.00 | 19.39 | 36.94 | 50.95 |
|
Payable days
|
63.88 | 74.11 | 45.04 | 149.20 | 46.50 |
|
Cash Conversion Cycle
|
61.99 | -24.81 | 30.08 | -92.25 | 55.43 |